Shaperon
Shaperon is a clinical stage biotech company dedicated to developing innovative therapies, including inflammasome inhibitors and Nanobody therapeutics, with a mission to lead innovation in the global healthcare market through the development of cutting-edge therapies. The company emphasizes continuous technological innovation, collaboration with global research institutions, and sustainable growth, aiming to contribute to global disease management and achieve a leadership position in the biotech industry.
Industries
Nr. of Employees
small (1-50)
Shaperon
174-10 Jagok-ro, Gangnam-gu, Seoul, South Korea
Patents
Pharmaceutical composition for prevention, treatment or delay of Alzheimer's disease or dementia containing G protein-coupled receptor 19 agent as active ingredient
US-10342807-B2
View DetailsPharmaceutical composition for prevention, treatment or delay of Alzheimer's disease or dementia containing G protein-coupled receptor 19 agent as active ingredient
US-10071107-B2
View DetailsComposition comprising GPCR19 agonist as an active ingredient for preventing or treating allergic dermatitis
US-9855283-B2
View DetailsComposition comprising GPCR19 agonist as an active ingredient for preventing or treating allergic dermatitis
US-9629854-B2
View DetailsUse of biological surfactant as anti-inflammatory agent and tissue preservative solution
US-9272047-B2
View Details
Pharmaceutical composition for prevention, treatment or delay of Alzheimer's disease or dementia containing G protein-coupled receptor 19 agent as active ingredient
US-10342807-B2
View DetailsPharmaceutical composition for prevention, treatment or delay of Alzheimer's disease or dementia containing G protein-coupled receptor 19 agent as active ingredient
US-10071107-B2
View DetailsComposition comprising GPCR19 agonist as an active ingredient for preventing or treating allergic dermatitis
US-9855283-B2
View DetailsComposition comprising GPCR19 agonist as an active ingredient for preventing or treating allergic dermatitis
US-9629854-B2
View DetailsUse of biological surfactant as anti-inflammatory agent and tissue preservative solution
US-9272047-B2
View DetailsProducts
Oral GPCR19–P2X7 modulator (HY209) for idiopathic pulmonary fibrosis
Oral small-molecule candidate that modulates GPCR19–P2X7 signaling to inhibit NLRP3 inflammasome activation; demonstrated anti-inflammatory and anti-fibrotic effects in bleomycin-induced pulmonary fibrosis models and is undergoing early clinical evaluation.
Oral GPCR19–P2X7 modulator (HY209) for idiopathic pulmonary fibrosis
Oral small-molecule candidate that modulates GPCR19–P2X7 signaling to inhibit NLRP3 inflammasome activation; demonstrated anti-inflammatory and anti-fibrotic effects in bleomycin-induced pulmonary fibrosis models and is undergoing early clinical evaluation.
Services
Platform leveraging large-scale training data and multiple algorithms to identify and optimize small-molecule and biologic candidates using predictive and generative modeling.
End-to-end nanobody discovery service including immunized-library generation, phage-display screening, rapid cloning and high-throughput validation, and modality engineering for multi-specific biologics and alternative formulations.
Platform leveraging large-scale training data and multiple algorithms to identify and optimize small-molecule and biologic candidates using predictive and generative modeling.
End-to-end nanobody discovery service including immunized-library generation, phage-display screening, rapid cloning and high-throughput validation, and modality engineering for multi-specific biologics and alternative formulations.
Expertise Areas
- AI-driven drug discovery
- Nanobody (single-domain antibody) discovery and engineering
- Inflammasome-targeted therapeutic development
- Preclinical in vivo efficacy testing
Key Technologies
- AI predictive and generative modeling
- In silico ADMET prediction
- Nanobody (single-domain antibody) platforms
- Phage display multiplex screening